Lu-177-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial

Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Lancet Oncology Elsevier: Lancet

Book Volume: 22

Pages Range: 1752-1763

Journal Issue: 12

DOI: 10.1016/S1470-2045(21)00572-6

Abstract

Background The primary analysis of the phase 3 NETTER-1 trial showed significant improvement in progression-free survival with Lu-177-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide alone in patients with advanced midgut neuroendocrine tumours. Here, we report the prespecified final analysis of overall survival and long-term safety results.

Authors with CRIS profile

Marianne Ellen Pavel Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Involved external institutions

MD Anderson Cancer Center Madrid

Spain (ES) Novartis AG

Switzerland (CH) University of Texas MD Anderson Cancer Center

United States (USA) (US) Beaujon Hospital / Hôpital Beaujon

France (FR) H. Lee Moffitt Cancer Center & Research Institute

United States (USA) (US) Icahn School of Medicine at Mount Sinai

United States (USA) (US) Erasmus University Medical Center (MC)

Netherlands (NL) Cedars-Sinai Medical Center

United States (USA) (US) Oregon Health and Science University (OSHU)

United States (USA) (US) Memorial Sloan Kettering Cancer Center

United States (USA) (US) Yale University

United States (USA) (US) Fondazione IRCCS: Istituto Nazionale dei Tumori

Italy (IT) Instituto Português de Oncologia Francisco Gentil (IPO) / Portuguese Oncology Institute

Portugal (PT) Royal Free Hospital

United Kingdom (GB) Katholieke Universiteit Leuven (KUL) / Catholic University of Leuven

Belgium (BE)

How to cite

APA:

Strosberg, J.R., Caplin, M.E., Kunz, P.L., Ruszniewski, P.B., Bodei, L., Hendifar, A.,... Krenning, E.P. (2021). Lu-177-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncology, 22(12), 1752-1763. https://doi.org/10.1016/S1470-2045(21)00572-6

MLA:

Strosberg, Jonathan R., et al. "Lu-177-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial." Lancet Oncology 22.12 (2021): 1752-1763.

BibTeX: Download